title: Incidence and management of edema associated with trebananib (AMG 386).
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arizona Cancer Center, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. Bradley.monk@chw.edu
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.forename: Lindsey
authors.initials: L
authors.lastname: Minion
authors.forename: Sandrina
authors.initials: S
authors.lastname: Lambrechts
authors.forename: Ignace B
authors.initials: IB
authors.lastname: Vergote
authors.forename: Nele
authors.initials: N
authors.lastname: Devoogdt
authors.forename: Beth Y
authors.initials: BY
authors.lastname: Karlan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000077216:Carcinoma, Ovarian Epithelial; D004487:Edema / Q000139:chemically induced* / Q000628:therapy*; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C551398:trebananib
keywords: AMG 386; Anti-angiogenic agent; Edema; Ovarian cancer; Trebananib